Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:28PM ET
12.10
Dollar change
+0.19
Percentage change
1.60
%
Index- P/E- EPS (ttm)-19.78 Insider Own0.69% Shs Outstand1.24M Perf Week-0.08%
Market Cap15.00M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.23M Perf Month-11.03%
Income-15.95M PEG- EPS next Q- Inst Own12.69% Short Float0.77% Perf Quarter-20.86%
Sales111.12M P/S0.14 EPS this Y- Inst Trans-55.85% Short Ratio2.47 Perf Half Y-22.54%
Book/sh61.13 P/B0.20 EPS next Y- ROA-4.20% Short Interest0.01M Perf Year6.14%
Cash/sh26.88 P/C0.45 EPS next 5Y46.00% ROE-23.68% 52W Range8.98 - 24.20 Perf YTD-19.81%
Dividend Est.- P/FCF- EPS past 5Y35.15% ROI-6.55% 52W High-49.99% Beta1.41
Dividend TTM- Quick Ratio1.21 Sales past 5Y-25.86% Gross Margin59.49% 52W Low34.77% ATR (14)0.77
Dividend Ex-Date- Current Ratio1.59 EPS Y/Y TTM90.77% Oper. Margin-29.68% RSI (14)41.65 Volatility4.21% 5.42%
Employees122 Debt/Eq3.16 Sales Y/Y TTM-10.43% Profit Margin-14.35% Recom1.00 Target Price200.00
Option/ShortNo / Yes LT Debt/Eq3.13 EPS Q/Q37.27% Payout- Rel Volume0.37 Prev Close11.91
Sales Surprise- EPS Surprise- Sales Q/Q-17.30% EarningsNov 13 AMC Avg Volume3.84K Price12.10
SMA20-5.37% SMA50-16.13% SMA200-10.28% Trades Volume1,015 Change1.60%
Date Action Analyst Rating Change Price Target Change
Jun-17-21Upgrade H.C. Wainwright Neutral → Buy $5 → $10
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Mar-25-24 04:01PM
Jan-11-24 08:01AM
Nov-14-23 10:34AM
Nov-13-23 04:07PM
04:01PM
04:01PM Loading…
Nov-06-23 04:01PM
08:00AM
Aug-28-23 12:42PM
Aug-08-23 04:21PM
04:01PM
Aug-02-23 08:00AM
Aug-01-23 08:00AM
Jun-28-23 05:08PM
Jun-26-23 08:23AM
Jun-05-23 09:06AM
04:01PM Loading…
Jun-02-23 04:01PM
May-31-23 04:01PM
May-30-23 08:00AM
May-12-23 05:28AM
May-11-23 04:29PM
04:01PM
02:26PM
May-10-23 07:00AM
May-08-23 07:00AM
May-04-23 09:41AM
Apr-24-23 08:00AM
Apr-03-23 08:00AM
Mar-27-23 08:00AM
Mar-09-23 07:00AM
Mar-07-23 07:00AM
03:43PM Loading…
Mar-06-23 03:43PM
Feb-14-23 04:46PM
Jan-31-23 04:01PM
Jan-05-23 04:20PM
Dec-22-22 08:00AM
Dec-20-22 05:30PM
Dec-05-22 07:01AM
Nov-19-22 08:12AM
Nov-11-22 09:52AM
Nov-04-22 09:25AM
Nov-01-22 04:01PM
Oct-27-22 07:00AM
Oct-25-22 04:01PM
Oct-21-22 07:00AM
Oct-19-22 07:00AM
Oct-18-22 07:00AM
Oct-16-22 04:48PM
Oct-10-22 06:30AM
Sep-08-22 04:01PM
Aug-29-22 07:00AM
Aug-19-22 08:00AM
Aug-04-22 04:01PM
Jul-28-22 04:01PM
Jun-16-22 09:31AM
07:01AM
May-11-22 04:01PM
04:01PM
May-04-22 04:01PM
Mar-09-22 04:01PM
Feb-24-22 05:00PM
Jan-04-22 07:11AM
Jan-03-22 04:01PM
Nov-09-21 04:01PM
04:01PM
Nov-02-21 07:00AM
Sep-09-21 08:01AM
Aug-05-21 05:45PM
04:01PM
Jul-30-21 04:01PM
Jul-27-21 03:02PM
Jul-23-21 07:28AM
Jul-22-21 04:01PM
Jun-18-21 10:46PM
Jun-16-21 07:00AM
May-06-21 05:15PM
04:00PM
Apr-29-21 04:30PM
Apr-27-21 12:00PM
Apr-20-21 09:46AM
Apr-12-21 07:00AM
Apr-01-21 07:51AM
Mar-12-21 10:01AM
Mar-11-21 08:52AM
Mar-10-21 11:30AM
Mar-08-21 11:12PM
05:44PM
Mar-05-21 08:15AM
Mar-04-21 05:45PM
04:01PM
Mar-03-21 12:52PM
Mar-02-21 08:43AM
Feb-26-21 10:10AM
Feb-25-21 07:00AM
Feb-19-21 07:00AM
Feb-11-21 11:12AM
09:13AM
07:00AM
Feb-10-21 10:21AM
Feb-08-21 12:40PM
Feb-04-21 11:48AM
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine), and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.